西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

薛梅萍; 郑茹萍; 林惠娥; 甘惠贞

doi:10.3969/j.issn.1006-0111.2018.05.020

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

薛梅萍, 郑茹萍, 林惠娥, 甘惠贞

文章导航 > 药学实践与服务 > 2018 > 36(5): 468-470

薛梅萍, 郑茹萍, 林惠娥, 甘惠贞. 西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究[J]. 药学实践与服务, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020

引用本文:

XUE Meiping, ZHENG Ruping, LIN Huie, GAN Huizhen. Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020

Citation:

XUE Meiping, ZHENG Ruping, LIN Huie, GAN Huizhen. Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020

西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

doi: 10.3969/j.issn.1006-0111.2018.05.020

解放军180医院药学科, 福建泉州 362000

Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

Department of Pharmacy, No. 180 Hospital of PLA, Quanzhou 362000, China

摘要: 目的探讨西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的疗效和安全性。方法采用回顾性分析法，收集解放军180医院内分泌科门诊脆性糖尿病伴高脂血症患者158例，其中，单用预混胰岛素治疗的78例为对照组，西格列汀联合预混胰岛素治疗的80例为治疗组，随访时间为36周。比较两组治疗前后糖化血红蛋白（HbAlc）、空腹血糖（FPG）、餐后血糖（PPG）、空腹C肽、餐后2 h C肽，每日血糖谷峰浓度均差（△TP）、血脂水平变化及低血糖发生率。结果治疗后联合组FPG、PPG、△TP、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）较治疗前均有明显下降（P<0.05，P<0.01），且均低于对照组（P<0.05，P<0.01）；联合组空腹C肽和餐后2 h C肽较治疗前显著升高（P<0.01），且均高于对照组（P<0.05）。结论西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症可显著改善患者血糖和血脂水平，且不良反应更少。
- 脆性糖尿病 /
- 西格列汀 /
- 预混胰岛素 /
- 疗效 /
- 安全性
Abstract: Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.
- brittle diabetes /
- sitagliptin /
- premixed insulin /
- efficacy /
- safety

[1]	VANTYGHEM MC,PRESS M. Management strategies for brittle diabetes[J]. Ann Endocrinol(Paris),2006,67(4):287-296.
[2]	AMETOV AS,KULIDZHANIAN NK. Diabetes mellitus is an independent risk factor for cardiovascular disease[J]. Ter Arkh,2012,84:91-94.
[3]	KIM D,WANG L,BECONI M,et al. (2R)-4-oxo-4-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2005,48(6):141-151.
[4]	DRUKER DJ, NAUCK MA. GLP-1R agonists(incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes[J]. Lancet, 2006, 368(3):1696-1705.
[5]	DRUCKER DJ. Enhancing incretin action for the treatment of type 2 diabetes[J]. Diabetes Care,2003,26(10):2929-2940.
[6]	LIU XM. Special complication of diabetes[M]//LIU Xinmin. Practical endocrinology. 2nd ed. Beijing:People's Military Medical Publishing House, 1997:356-358.
[7]	郭慧,刘良专,刘江华. 降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高血脂症患者效果观察[J]. 重庆医学,2015,44(24):3348-3349.
[8]	HOLST JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide 1[J]. Diabetes Metab Res Rev,2002,18(6):430-441.
[9]	徐晓菲,吴玉波,吴禹蒙. 西格列汀对2型糖尿病患者血脂水平影响的系统评价[J]. 中国药房,2015,26(6):784-787.
[10]	罗娜,朱妍,张真稳,等. 西格列汀联合胰岛素治疗脆性糖尿病的临床观察[J]. 中南大学学报(医学版),2015,40(10):1089-1095.

[1]	徐航, 王天宇, 张灵娜, 宋洪涛. 液体创可贴的质量控制标准与安全性研究 . 药学实践与服务, 2023, 41(2): 106-112, 129. doi: 10.12206/j.issn.2097-2024.202103063
[2]	李婷, 时扣荣, 李智, 王子玉, 曹爱霖, 钱皎. 达比加群酯治疗老年非瓣膜性心房颤动的有效性和安全性评价 . 药学实践与服务, 2023, 41(9): 557-560. doi: 10.12206/j.issn.2097-2024.202207029
[3]	魏恂, 高珊. Bimekizumab治疗中/重度斑块状银屑病的疗效与安全性的系统评价 . 药学实践与服务, 2023, 41(7): 449-454. doi: 10.12206/j.issn.2097-2024.202203089
[4]	曾娜, 王超, 孙华君, 马丽平, 董晓艳. 奥马珠单抗治疗2例高水平IgE过敏性哮喘患儿的用药监护 . 药学实践与服务, 2022, 40(4): 368-371. doi: 10.12206/j.issn.1006-0111.202205109
[5]	侯文洁, 张亮, 李翔宇, 王洁. CYP2C19基因多态性对PCI术后患者氯吡格雷血药浓度、血小板抑制率和安全性的影响 . 药学实践与服务, 2021, 39(5): 472-475. doi: 10.12206/j.issn.1006-0111.202008029
[6]	熊明彪, 曹辉, 杨德钱. 连花清瘟胶囊对比奥司他韦治疗流行性感冒疗效和安全性的Meta分析 . 药学实践与服务, 2021, 39(5): 454-459. doi: 10.12206/j.issn.1006-0111.202012021
[7]	严佳, 吴博, 陶春, 宋洪涛. 自制复方酮康唑软膏的药效学和安全性研究 . 药学实践与服务, 2020, 38(4): 322-327. doi: 10.12206/j.issn.1006-0111.201909078
[8]	吴思凡, 谭长宇, 樊红彬, 印晓星, 鲁茜. 奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析 . 药学实践与服务, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
[9]	李新方, 李现贵, 马志强, 钟延强, 高钰琪, 杨峰. 薄荷脑鼻腔原位凝胶剂的制备及安全性研究 . 药学实践与服务, 2017, 35(4): 321-324,366. doi: 10.3969/j.issn.1006-0111.2017.04.008
[10]	蔡建, 李明明, 张平, 费春华, 钱昌, 徐峰. 门诊抑郁患者的药物品牌偏好及对用药依从性和疗效的影响 . 药学实践与服务, 2017, 35(2): 154-157,164,181. doi: 10.3969/j.issn.1006-0111.2017.02.014
[11]	孙慧, 张莎莎, 连炜炜. 中药清湿热解毒配方颗粒治疗高尿酸血症的临床疗效及安全性评价 . 药学实践与服务, 2016, 34(1): 79-82,92. doi: 10.3969/j.issn.1006-0111.2016.01.021
[12]	樊蓉, 任天舒, 赵庆春, 史国兵. 西药常规治疗联用通心络胶囊治疗冠心病心绞痛疗效的荟萃分析 . 药学实践与服务, 2015, 33(1): 83-87. doi: 10.3969/j.issn.1006-0111.2015.01.024
[13]	魏若菡, 张晨虹, 杨心宇. 补充维生素B在老年性阴道炎治疗中的作用 . 药学实践与服务, 2014, 32(3): 220-221,224. doi: 10.3969/j.issn.1006-0111.2014.03.015
[14]	李阳, 王红力. 吸入用布地奈德混悬液治疗上气道咳嗽综合征疗效观察 . 药学实践与服务, 2013, 31(5): 355-356. doi: 10.3969/j.issn.1006-0111.2013.05.009
[15]	黄秋明, 涂雪松, 晏琼, 史传林. 马来酸桂哌齐特治疗糖尿病周围神经病变的Meta分析 . 药学实践与服务, 2012, 30(2): 137-142. doi: 10.3969/j.issn.1006-0111.2012.02.016
[16]	陈翊, 濮剑英. 噻托溴铵对中重度慢性阻塞性肺病的治疗效果 . 药学实践与服务, 2012, 30(3): 213-215. doi: 10.3969/j.issn.1006-0111.2012.03.015
[17]	侯明明, 宋洪涛, 王庆华, 杨顺良, 谭建明. 肾移植患者MDR1C3435T基因多态性对他克莫司血药浓度/剂量比及疗效的影响 . 药学实践与服务, 2010, 28(1): 29-31.
[18]	刘福强, 车延志, 孙丹, 赵惠莹. ^99mTc研究胃漂浮片试验的安全性和影响因素 . 药学实践与服务, 2009, 27(2): 104-106,110.
[19]	张治然, 刁天喜, 高云华. 生物医药的安全性及其对策 . 药学实践与服务, 2009, 27(5): 375-377.
[20]	白燕萍, 任静. 紫外线负离子喷雾联合阿昔洛韦治疗带状疱疹疗效观察 . 药学实践与服务, 2004, (6): 342-343.

点击查看大图

计量

文章访问数: 2485
HTML全文浏览量: 278
PDF下载量: 359
被引次数: 0

西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

doi: 10.3969/j.issn.1006-0111.2018.05.020

解放军180医院药学科, 福建泉州 362000

收稿日期: 2017-12-19
修回日期: 2018-03-05

关键词:

疗效 /

摘要: 目的探讨西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的疗效和安全性。方法采用回顾性分析法，收集解放军180医院内分泌科门诊脆性糖尿病伴高脂血症患者158例，其中，单用预混胰岛素治疗的78例为对照组，西格列汀联合预混胰岛素治疗的80例为治疗组，随访时间为36周。比较两组治疗前后糖化血红蛋白（HbAlc）、空腹血糖（FPG）、餐后血糖（PPG）、空腹C肽、餐后2 h C肽，每日血糖谷峰浓度均差（△TP）、血脂水平变化及低血糖发生率。结果治疗后联合组FPG、PPG、△TP、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）较治疗前均有明显下降（P<0.05，P<0.01），且均低于对照组（P<0.05，P<0.01）；联合组空腹C肽和餐后2 h C肽较治疗前显著升高（P<0.01），且均高于对照组（P<0.05）。结论西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症可显著改善患者血糖和血脂水平，且不良反应更少。

English Abstract

Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

Department of Pharmacy, No. 180 Hospital of PLA, Quanzhou 362000, China

Received Date: 2017-12-19
Rev Recd Date: 2018-03-05

Keywords:

Abstract: Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.

引用本文:

Citation:

XUE Meiping, ZHENG Ruping, LIN Huie, GAN Huizhen. Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020